2023
Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study
Najjar-Debbiny R, Barnett-Griness O, Khoury J, Gronich N, Weber G, Adir Y, Shteinberg M, Shneir S, Sharma L, Saliba W. Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study. The American Journal Of Medicine 2023, 136: 1087-1093.e2. PMID: 37598922, DOI: 10.1016/j.amjmed.2023.07.020.Peer-Reviewed Original ResearchPulmonary fibrosisCase-control studyCOVID-19 severityCOVID-19Multivariable conditional logistic regression modelsNested Case-Control StudyConditional logistic regression modelsSevere COVID-19Prior COVID-19COVID-19 infectionLogistic regression modelsLargest healthcare providerUnderlying cohortCohort entrySignificant morbiditySurveillance biasOdds ratioSevere diseaseFibrosisHealthcare providersCoronavirus diseaseCalendar timePatientsCohortLag timeVISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis.
Kim S, Adams T, Hu Q, Shin H, Chae G, Lee S, Sharma L, Kwon H, Lee F, Park H, Huh W, Manning E, Kaminski N, Sauler M, Chen L, Song J, Kim T, Kang M. VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis. American Journal Of Respiratory Cell And Molecular Biology 2023, 69: 22-33. PMID: 36450109, PMCID: PMC10324045, DOI: 10.1165/rcmb.2022-0219oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisImmune regulatorsTherapeutic potentialHuman idiopathic pulmonary fibrosisCrucial immune regulatorsNovel immune regulatorPulmonary fibrosis micePulmonary fibrosis modelNovel therapeutic targetRole of VISTAWild-type littermatesMonocyte-derived macrophagesT lymphocyte lineageVISTA expressionIPF treatmentAntibody treatmentImmune landscapeFibrotic mediatorsLung fibrosisFibrosis miceInflammatory responseFibrosis modelMyeloid populationsTherapeutic targetmicroRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosis
Ahangari F, Price N, Malik S, Chioccioli M, Bärnthaler T, Adams T, Kim J, Pradeep S, Ding S, Cosme C, Rose K, McDonough J, Aurelien N, Ibarra G, Omote N, Schupp J, DeIuliis G, Nunez J, Sharma L, Ryu C, Dela Cruz C, Liu X, Prasse A, Rosas I, Bahal R, Fernandez-Hernando C, Kaminski N. microRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosis. JCI Insight 2023, 8: e158100. PMID: 36626225, PMCID: PMC9977502, DOI: 10.1172/jci.insight.158100.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisMiR-33MiR-33 levelsSpecific genetic ablationBronchoalveolar lavage cellsNovel therapeutic approachesMitochondrial homeostasisFatty acid metabolismMacrophages protectsBleomycin injuryLavage cellsLung fibrosisHealthy controlsInflammatory responseTherapeutic approachesImmunometabolic responsesCholesterol effluxFibrosisFatal diseasePharmacological inhibitionSterol regulatory element-binding protein (SREBP) genesGenetic ablationMacrophagesEx vivo mouse
2022
Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.
Ahangari F, Becker C, Foster DG, Chioccioli M, Nelson M, Beke K, Wang X, Justet A, Adams T, Readhead B, Meador C, Correll K, Lili LN, Roybal HM, Rose KA, Ding S, Barnthaler T, Briones N, DeIuliis G, Schupp JC, Li Q, Omote N, Aschner Y, Sharma L, Kopf KW, Magnusson B, Hicks R, Backmark A, Dela Cruz CS, Rosas I, Cousens LP, Dudley JT, Kaminski N, Downey GP. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2022, 206: 1463-1479. PMID: 35998281, PMCID: PMC9757097, DOI: 10.1164/rccm.202010-3832oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisHuman precision-cut lung slicesPrecision-cut lung slicesPulmonary fibrosisNormal human lung fibroblastsEpithelial-mesenchymal transitionHuman lung fibroblastsFibrogenic pathwaysPreclinical modelsMurine modelLung slicesSrc kinase inhibitorLung fibroblastsKinase inhibitorsAmelioration of fibrosisSelective Src kinase inhibitorHuman lung fibrosisWhole lung extractsPotential therapeutic efficacyIPF diseaseIPF treatmentLung functionInflammatory cascadeLung fibrosisAntifibrotic efficacy
2020
Chitotriosidase: a marker and modulator of lung disease
Chang D, Sharma L, Dela Cruz CS. Chitotriosidase: a marker and modulator of lung disease. European Respiratory Review 2020, 29: 190143. PMID: 32350087, PMCID: PMC9488994, DOI: 10.1183/16000617.0143-2019.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2019
Measurement of Chitinase Activity in Biological Samples.
Amick AK, Liu Q, Gautam S, Chupp G, Dela Cruz CS, Sharma L. Measurement of Chitinase Activity in Biological Samples. Journal Of Visualized Experiments 2019 PMID: 31498326, DOI: 10.3791/60159.Peer-Reviewed Original ResearchConceptsDisease severityType 2 inflammatory diseasesPulmonary fibrosisAllergic diseasesInflammatory diseasesHost immunityReliable biomarkersTherapeutic effectivenessGaucher diseaseHost defenseSerum samplesDiseaseChitinase-like proteinsGenetic disordersHuman subjectsPrecise roleImportant biomarkerBiomarkersSeverityImportant roleChitinase levelsAsthmaPatientsFibrosisMice